Zusammenfassung
Wenn schon die Prävention einer schizophrenen Ersterkrankung nicht gelingt, so wäre doch mit der Verhinderung einer Wiedererkrankung, also einer erfolgreichen Rezidivprophylaxe, ein Ziel der sekundären Prävention erreicht.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Gaebel W, Pietzcker A, Poppenberg A (1981) Prädiktoren des Verlaufs schizophrener Erkrankungen unter neuroleptischer Langzeitmedikation. Pharmakopsychiatr Neuropsycho-pharmakol 14:180–188
Gibson AC (1978) Depot Injections and Tardive Dyskinesia. Br J Psychiatry 133:361–365
Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 49:534–538
Hippius H, Lange J (1970) Zur Problematik der späten extrapyramidalen Hyperkinesen nach langfristiger neuroleptischer Therapie. Arzneim Forsch/Drug Res 20:888–890
Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974) Drug and Sociotherapy in the Aftercare of Schizophrenic Patients: Two Year Relapse Rates. Arch Gen Psychiatry 31:603–608
Hogarty GE, Ulrich RF, Mussare F, Arishgueta N (1976) Drug Discontinuation Among Long Term, Successfully Maintained Schizophrenic Outpatient. Dis Nerv Syst 37:494–500
Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients. Arch Gen Psychiatry 36:1283–1294
Jeste DV, Wyatt RJ (1981) Changing Epidemiology of Tardive Dyskinesia: An Overview. Am J Psychiatry 138:297–309
Jeste DV, Wyatt RJ (1982) Therapeutic Strategies Against Tardive Dyskinesia. Two Decades of Experience. Arch Gen Psychiatry 39:803–816
Kane JM, Rifkin A, Quitkin F, Nayak D, Saraf K, Ramos-Lorenzi JR, Klein DF, Sachar EJ (1979) Low Dose Fluphenazine Decanoate in Maintenance Treatment of Schizophrenia. Psychiatry Res 1:341–348
Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982) Fluphenazine vs Placebo in Patients with Remitted, Acute First-Episode Schizophrenia. Arch Gen Psychiatry 39:70–73
Kane JM, Smith JM (1982) Tardive Dyskinesia. Prevalence and Risk Factors, 1959 to 1979. Arch Gen Psychiatry 39: 473–481
Kane JM, Rifkin A, Woerner M, Reardon G (1982) Low-Dose Neuroleptics in Outpatient Schizophrenics. Psychopharmacol Bull 18:20–21
Leff JP, Wing JK (1971) Trial of Maintenance Therapy in Schizophrenia. Br Med J 3:599–604
Leff J, Kuipers L, Berkowitz R, Eberlein-Vries R, Sturgeon D (1982) A Controlled Trial of Social Intervention in the Families of Schizophrenic Patients. Br J Psychiatry 141:121–134
Levine J, Schooler NR, Cassano GB (1979) The Role of Depot Neuroleptics in the Treatment of Schizophrenic Patients. Psychol Med 9:383–386
May PRA, Goldberg SC (1978) Prediction of Schizophrenic Patients’ Response to Pharmacotherapy. Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A Generation of Progress. Raven Press, New York, pp 1139–1153
May PRA, Simpson GM (1980) Schizophrenia: Evaluation of Treatment Methods. Kaplan HI, Freedman AM, Sadock BJ (eds) Comprehensive Textbook of Psychiatry/III Volume 2 — Third Edition. Williams & Wilkins, Baltimore/London, pp 1240–1275
Müller P (Hrsg) (1982) Zur Rezidivprophylaxe schizophrener Psychosen. Ergebnisse einer Doppelblinduntersuchung. Enke, Stuttgart
Pietzcker A (1978) Langzeitmedikation bei schizophrenen Kranken. Nervenarzt 49:518–533
Pietzcker A, Poppenberg A, Schley J, Müller-Oerlinghausen B (1981) Outcome and Risks of Ultra-Long-Term Treatment with an Oral Neuroleptic Drug. Relationship Between Perazine Serum Levels and Clinical Variables in Schizophrenic Outpatients. Arch Psychiatr Nervenkr 229:315–329
Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine Decanoate, Fluphenazine Hydrochloride Given Orally and Placebo in Remitted Schizophrenics. I. Relapse Rates after One Year. Arch Gen Psychiatry 34:43–47
Schooler NR, Levine JL, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of Relapse in Schizophrenia. Arch Gen Psychiatry 37: 16–24
Wistedt B (1981) A Depot Neuroleptic Withdrawal Study. A Controlled Study of the Clinical Effects of the Withdrawal of Depot Fluphenazine Decanoate and Depot Flupenthixol Decanoate in Chronic Schizophrenic Patients. Acta Psychiatr Scand 64:65–84
Woggon B (1979) Neuroleptika-Absetzversuche bei chronisch schizophrenen Patienten. I. Literaturzusammenfassung. Int Pharmacopsychiatry 14:34–56
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pietzcker, A. (1984). Neuroleptische Langzeitmedikation zur Rezidivprophylaxe schizophrener Erkrankungen. In: Rudolf, G.A.E., Tölle, R. (eds) Prävention in der Psychiatrie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69852-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-69852-1_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13580-7
Online ISBN: 978-3-642-69852-1
eBook Packages: Springer Book Archive